SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending amid a mixed sentiment, with some traders pointing to a recent report highlighting security flaws in its battlefield communication system while others dismiss it as a hit piece designed to create a buying opportunity. The community is actively debating the company's valuation and future growth prospects in the AI space, with some calling it overvalued and others believing it has significant long-term potential. Despite the debate, some are taking advantage of the dip and loading up on shares, anticipating a rebound.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members highlight its potential as a culture coin and a symbol of freedom within the digital currency space. The project is drawing attention for its association with the cannabis culture and its aim to provide a decentralized financial tool. Community is also celebrating the 420k BURN event with a livestream, calling it a significant step for the project.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending after announcing a partnership with Perplexity AI to enhance content discovery and bundle services, sparking community excitement about AI integration. Discussions also revolve around Rumble's ties to cryptocurrency through Tether and potential benefits from a Trump administration. Some traders are eyeing a potential short squeeze given the high short interest.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid excitement over the company's shift to quantum computing for cryptocurrency applications, particularly its partnership related to LightSolver's laser-based processing units. The community is actively discussing the potential for energy savings and comparing it to other trending quantum stocks. Some traders are closely watching its threshold list status and awaiting news of potential contracts.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending due to Citron Research's positive outlook, sparking significant trading volume and community discussion about a potential short squeeze. Community members are debating the company's long-term prospects, comparing it to other telehealth plays, and speculating on factors such as potential acquisitions and partnerships. Overall, the conversation centers on whether Teladoc is undervalued and poised for a breakout.

Astrotech Corp. engages in the mass spectrometry company that launches, manages and commercializes scalable companies based on its innovative core technology through its wholly-owned subsidiaries. Its business units include 1st Detect, BreathTech, and AgLab. The company was founded in 1984 and is headquartered in Austin, TX.

Astrotech Corp

ASTC is experiencing high volatility and significant volume, leading to a surge in price. The community is actively discussing profit-taking strategies and potential breakout levels. The stock's momentum and low float are key factors driving the current interest.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is trending due to discussions surrounding potential White House talks and government funding related to rare earth minerals. Community members are speculating on a potential deal with the Trump administration to boost domestic supply and reduce reliance on China. Some traders are noting the stock's breakout, short interest, and sector momentum, while others remain skeptical.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending as traders discuss its potential for a squeeze, with some anticipating a rise to $10 or even $20. This speculation follows news of FDA Fast Track designation for ALTO-101 and investors are actively monitoring chat rooms, hoping for a breakout. The community also discusses the company's financials, pipeline and potential readouts.

American Rebel Holdings, Inc. engages in the design and marketing of branded safes, and personal security and self-defense products. It also designs and manufactures branded apparel and accessories. The company was founded on December 15, 2014 and is headquartered in Brentwood, TN.

American Rebel Holdings Inc

American Rebel Holdings (AREB) is trending amidst discussions about a potential "free money" opportunity related to an upcoming reverse stock split and a 100-share round lot clause, with some traders strategizing around this event. The community is actively debating the implications of selling shares before receiving additional shares, and scrutinizing page 37 of a recent filing for clarification. Some express concerns about reverse splits and leadership, while others remain optimistic about a potential spike similar to past events.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as traders discuss a potential short squeeze and significant call option buying, particularly for the October 17th expiry. Community members are debating the stock's valuation, with some citing a past buyout offer and strong fundamentals despite a recent price drop. Discussions also involve speculation about insider trading and the potential for a Merck deal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know

Candel Therapeutics (CADL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect?

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Shares of Candel Therapeutics, Inc. (CADL) traded 8% higher on Wednesday morning after the U.S. Food and Drug Administration (FDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-regenerative-medicine-advanced">granted</a> Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate CAN-2409 for the treatment of a certain kind of prostate cancer.CAN-2409 is being studied for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and was previously granted FDA Fast Track designation for the same indication.RMAT designations are intended to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse, or cure serious or life-threatening diseases where preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.Candel’s lead candidate was granted the designation based on positive data from a late-stage trial evaluating the efficacy and safety of the investigational drug plus a prodrug, together with external beam radiation therapy, in newly diagnosed, localized, intermediate-to-high-risk prostate cancer.Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application (BLA) seeking permission to commercialize. The company is looking to submit the application by the end of 2026.RMAT designations offer the company access to mechanisms designed to fast-track BLA review and approval.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_10_27_02_AM_png_786b86992f.webp" alt="CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits " width="628" height="63"><figcaption>CADL's Sentiment Meter and Message Volume as of 10:25 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>A Stocktwits user opined that the shares are suitable for holding in the mid- to long-term.<stembedurl>https://stocktwits.com/Bowlofpasta/message/616040223</stembedurl>According to data from Koyfin, all three analysts covering CADL rate it a ‘Buy.’ The stock has an average price target of $21.67, implying an upside of over 200% from its current value.<a href="https://stocktwits.com/symbol/CADL">CADL stock</a> is down by about 33% this year and by about 30% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/macys-q1-earnings-tops-estimates/ch0okCjRbsh">Macy’s Q1 Earnings Top Estimates, But Company Cuts 2025 Guidance Over Tariff Concerns, Weaker Consumer Sentiment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy

Candel CEO Paul Peter Tak said that the company looks forward to collaborating with the FDA on an expedited approval for the immunotherapy candidate once it submits its Biologics License Application.

Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy

Equity

Best Momentum Stocks to Buy for May 19th

Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's  What You Should Know

Shares of Candel Therapeutics, Inc. (CADL) surged nearly 10% on Tuesday afternoon after the company reported upbeat first-quarter (Q1) earnings.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results">reported</a> diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024, and surpassing an estimated loss of $0.35 per share, as per Finchat data.It said the rise in net income was primarily related to the change in the fair value of the company’s warrant liability.While research and development expenses narrowed year-on-year in the quarter, general and administrative expenses rose.The biopharmaceutical company ended the first quarter with cash and cash equivalents of $92.2 million compared to $102.7 million as of Dec. 31, 2024. Candel expects that its existing cash and cash equivalents will be sufficient to fund its current operating plan into the first quarter of 2027.CEO Paul-Peter Tak said that the company’s primary focus for 2025 remains working toward submitting an application to the U.S. Food and Drug Administration (FDA) for the commercialisation of its investigational immunotherapy candidate and lead asset CAN-2409 for the treatment of prostate cancer. The submission is expected in the fourth quarter of 2026.“We are now focusing on executing strategic preparations for potential commercialization, to ensure that, if approved, CAN-2409 is immediately available to patients with localized prostate cancer,” he said.CAN-2409 is also being studied for the treatment of pancreatic cancer and non-small cell lung cancer.On Stocktwits, retail sentiment around Candel rose within the ‘bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:628/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_1_41_07_PM_png_6a3877db5b.webp" alt="CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits" width="628" height="62"><figcaption>CADL's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CADL/sentiment">CADL stock</a> is down by about 39% this year and 46% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amd-google-uber-stocks-rally-after-committing-to-invest-80-b-in-600b-us-saudi-deal/chi8AJjRbZN">AMD, Google, Uber Stocks Rally After Committing To Invest $80B As Part Of US-Saudi $600B Trade Pact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Candel Therapeutics Stock Jumps On Upbeat Q1 Earnings: Retail Gets More Bullish

The company reported diluted net income per share of $0.13 for the three months through the end of March, compared to a loss of $0.28 in the corresponding period of 2024.

Candel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced encouraging data from a cancer drug trial.The company reported final survival data from a Phase 2a trial of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">CAN-2409</a> in advanced lung cancer patients who did not respond well to immune checkpoint inhibitors (ICI).&nbsp;The median overall survival (mOS) was 24.5 months for those receiving two courses of CAN-2409, significantly higher than the 9.8-11.8 months seen in similar patients receiving standard chemotherapy.The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years.&nbsp;Patients with non-squamous non-small cell lung cancer (NSCLC) showed the most potent response, with a mOS of 25.4 months in this group. Biomarker analysis indicated a stronger immune response in these patients than in those with squamous NSCLC.The treatment also appeared to induce a systemic immune response, as 69% of patients with multiple tumors saw reductions in untreated lesions.&nbsp;CAN-2409 maintained a favorable safety profile throughout the extended follow-up period, the company added.The news sent message volume about Candel on Stocktwits soaring by over 120%, with sentiment climbing further within the ‘neutral’ territory (53/100) from a day ago.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/CADL_sentiment_and_message_volume_as_of_Macrh_26_png_1c49d17460.webp" alt="CADL sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>CADL sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One optimistic user said CAN-2409 "is worth billions," adding that Candel also had successful phase-3 trials in prostate cancer and a successful phase-2 in pancreatic cancer.<stembedurl>https://stocktwits.com/strategicmind/message/609387743</stembedurl>Another compared Candel to small-cap biotech firms that were acquired by established pharma giants such as Gilead and Pfizer for tens of billions of dollars, saying the company “will join this GOAT rodeo in no time.”<stembedurl>https://stocktwits.com/chrundel/message/609386559</stembedurl>“I could see this becoming [the] standard of care for adenocarcinoma of the lung,” said another user based on the data.<stembedurl>https://stocktwits.com/Uromaster/message/609354605</stembedurl>Last month, Candel shared updated survival data from Phase 2a trials of CAN-2409 in pancreatic cancer.&nbsp;Meanwhile, Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is expected in the fourth quarter of 2025, and the company plans to submit a Biologics License Application (BLA) for CAN-2409 in prostate cancer in Q4 2026.Candel stock is down about 12% this year but has gained more than 390% in the past 12 months.&nbsp;According to Koyfin, three out of four analysts covering Candel rate it ‘buy’ while one recommends a ‘strong buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration showing chimeric antigen receptor (CAR) T cells (blue and green) being used to treat non-small cell lung cancer (NSCLC). | Representative image: Getty Images

Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail Optimism

The study included 46 fully treated patients, with 37% of those with progressive disease still alive after two years. 

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street.Canaccord initiated coverage on the stock with a ‘Buy’ rating and a $20 price target, implying a 91% upside from the last close.&nbsp;The research firm expects continued clinical success for Candel’s lead asset, CAN-2409, in prostate, pancreatic, and non-small cell lung cancer.&nbsp;In testing so far, CAN-2409 has shown a significant increase in median overall survival. If this trend continues, it could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst.&nbsp;On Stocktwits, sentiment turned ‘extremely bullish’ on Wednesday as message volume jumped by 50% and new followers increased by 4%.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CADL_sentiment_and_message_volume_Feb_19_d3c9416772.png" alt="CADL sentiment and message volume Feb 19.png" width="1316" height="316"><figcaption>CADL sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Traders speculated that upcoming data could drive a major rally, with some predicting that strong results from the pancreatic study could push shares into the $30-$40 range.<stembedurl>https://stocktwits.com/Xanderzzzzzzz/message/604910450</stembedurl><stembedurl>https://stocktwits.com/drizz/message/604899234</stembedurl>Last week, BofA Securities also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-surges-on-bofa-buy-call/chPzAKRRtG">initiated</a> coverage on Candel with a ‘Buy’ rating and a $15 price target, citing promising early data for CAN-2409 and CAN-3110 as key drivers of its bullish outlook.&nbsp;The research firm noted that CAN-2409’s early results in prostate cancer suggest a potential breakthrough, while CAN-3110 has shown signs of nearly doubling overall survival in patients with recurrent high-grade glioma.Candel has outlined several key milestones ahead.&nbsp;Updated overall survival data from Phase 2a trials of CAN-2409 in pancreatic and non-small cell lung cancer is expected in the first quarter of 2025.&nbsp;Phase 1b survival data for CAN-3110 in recurrent high-grade glioma is set for the fourth quarter of 2025, while a Biologics License Application (BLA) submission for CAN-2409 in prostate cancer is targeted for the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/CADL">Candel stock</a> is up more than 22% this year. Short interest was 6.2% as of last week, down from 14.1% at the start of the year, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice

CAN-2409 could become a “best-in-class therapy” for borderline resectable pancreatic ductal adenocarcinoma, according to the analyst. 

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.18	--	--	N/A
Q2 '25	-$0.16	-$0.09	45.02%	BEAT
Q1 '25	-$0.37	$0.13	134.70%	BEAT
Q4 '24	-$0.23	-$0.40	-75.74%	MISSED
Q3 '24	--	-$0.33	--	N/A

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CADL News

CADL Candel Therapeutics Inc